Medical/Pharmaceuticals

In Indonesia, stroke care delays accumulate on the way to treatment, new report finds

Indonesian experts call for capability-based referral routing, greater investment in trained stroke teams and broader insurance coverage to close the gap between Western and Eastern Indonesia. JAKARTA, Indonesia, Sept. 3, 2026 /PRNewswire/ -- Structural delays occurring before patients reach tre...

2026-09-03 13:21 2047

Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults

SHANGHAI, Sept. 3, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that China's National Medical Product...

2026-09-03 13:20 2411

The Galien Foundation Announces the Nominees for the Inaugural 2026 Prix Galien Korea Awards

Historic First Edition Launches in Partnership with MK Media (Maekyung), Yozma Group Korea, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), and KoreaBIO at the World Knowledge Forum in Seoul SEOUL, South Korea, Sept. 3, 2026 /PRNewswire/ -- The Galien Foundation, the p...

2026-09-03 08:00 2085

EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

PROVIDENCE, R.I., Sept. 3, 2026 /PRNewswire/ -- EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements toISPRI™ , its proprietary in sili...

2026-09-02 23:19 1809

NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury

Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life - Spinal Cord Research Foundation. SCHLIEREN, Switzerland, Sept. 2, 2026 /PRNewswire/ -- NovaGo Therapeutics AG, a ...

2026-09-02 18:00 2564

BTL Establishes New Laser Division and Introduces EXOLASE ONE® - The World's First Fused Erbium Laser

Proprietary technology fuses multiple wavelengths into a single beam to set a new standard of care in laser facial rejuvenation. PRAGUE, Sept. 2, 2026 /PRNewswire/ -- BTL, a global leader in advanced energy-based medical and aesthetic technologies, today announced a major milestone in its corpor...

2026-09-02 16:00 1848

Singapore has cut stroke mortality by up to six-fold since the 1990s, but public awareness remains the final hurdle, new report finds

Singaporean experts call for renewed public education on the FAST warning signs and continued investment in specialist staffing to sustain the country's world-leading stroke outcomes. SINGAPORE, Sept. 2, 2026 /PRNewswire/ -- Singapore has cut stroke mortality by up to six-fold since the 1990s[1]...

2026-09-02 15:00 4929

Despite nationwide basic stroke treatment coverage, delays accessing advanced stroke care in Vietnam vary by region, new report finds

Patients in Vietnam's Southwest region and Mekong Delta can travel up to ten hours for advanced stroke care; Vietnamese experts point to a public-private model in Can Tho as a way to close that gap. HO CHI MINH CITY, Vietnam, Sept. 2, 2026 /PRNewswire/ -- Delays occurring before patients reach a...

2026-09-02 15:00 4549

Workforce shortages and limited public hospital capacity remain major barriers to stroke care in the Philippines, new report finds

Filipino experts call for equipping more public hospitals with advanced imaging technology, stronger EMS infrastructure and greater investment in specialist training to close these gaps MANILA, Philippines, Sept. 2, 2026 /PRNewswire/ -- Workforce shortages and limited public hospital capacity re...

2026-09-02 15:00 4926

Delays before patients reach stroke centres remain a major barrier to timely treatment in Malaysia, new report finds

Malaysia experts call for better public awareness of stroke symptoms, standardised hospital imaging protocols and expanded access to specialist care beyond major urban centres KUALA LUMPUR, Malaysia, Sept. 2, 2026 /PRNewswire/ -- Delays occurring before patients reach stroke centres remain a maj...

2026-09-02 15:00 5047

Delays Before Patients Reach Stroke Centers Still Hinder Timely Treatment Across Southeast Asia, Siemens Healthineers Report Finds

New research commissioned by Siemens Healthineers shows transportation delays, slow reporting processes as leading barriers to timely stroke diagnosis. * Stronger referral networks, public awareness, AI-enabled diagnostics, coordinated care are key to strengthening stroke system readiness acros...

2026-09-02 15:00 4947

"From Canine Fat Tissue to Insulin-Producing Cells": Chula Veterinary Researchers Offer New Hope for Diabetes Treatment in Pets

While diabetes is commonly associated with humans, the disease also affects dogs and cats. Its impact on the quality of life of both pets and their owners is often greater than many people realize. BANGKOK, Sept. 2, 2026 /PRNewswire/ -- In dogs, diabetes is similar to Type 1 diabetes in humans, ...

2026-09-02 14:23 3128

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

* The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. * Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement an...

2026-09-02 09:27 1834

Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026

Haier Biomedical Accelerates Its Transformation into an Intelligent Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026 SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Haier Biomedical  (SHA: 688139) showcased a portfolio of automated and digital solutions sp...

2026-09-01 22:50 3076

Super MOXI® by Sciton Ushers in a New Era of Head-to-Toe Skin Revitalization

PALO ALTO, Calif., Sept. 1, 2026 /PRNewswire/ -- Sciton Inc., a pioneer and leader in medical and aesthetic laser and light-based technologies, today announced the launch of Super MOXI® with High Density (HD) Delivery™, a major evolution of its award-winning MOXI® laser that brings new speed, ver...

2026-09-01 21:10 2468

Suki Named a Transformational Innovation Leader in Ambient Clinical Intelligence by Frost & Sullivan

2026 recognition highlights Suki's innovation, clinical quality and measurable impact as Ambient Clinical Intelligence expands across the enterprise SAN ANTONIO, Sept. 1, 2026 /PRNewswire/ -- Suki

2026-09-01 21:00 1702

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Pa...

2026-09-01 19:30 1960

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expec...

2026-09-01 19:15 2235

OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel

ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades of lega...

2026-09-01 19:00 2341

JIANGXI BIO Announced 2026 Interim Results

Overseas Contract Orders Reach Nearly RMB27.4 mn and R&D Translation Gains Momentum, with the AEPC Platform Reshaping the R&D Paradigm for Equine Polyclonal Antibody Interim Results Highlights   Key Financial Indicators * Revenue amounted to RMB83.3 mn; gross profit amounted to RMB60.3 mn, ...

2026-09-01 14:44 6088
123456 ... 383